Clinical Trial Update: A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating additional intravitreal RBM-007 injections for wet age-related macular degeneration completed with posted results in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exudative Age-related Macular Degeneration

Drugs mentioned

• RBM-007

Snippet

Sponsor: Ribomic USA Inc | Conditions: Exudative Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2023-06-08